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ABSTRACT
Background and the purpose of the study: A gastroretentive pH sensitive system has been a 
frontier approach to release the drug in controlled manner in stomach and duodenum. The aim 
of this study was to develop buoyant beads of gellan based, wherein, the oil was entrapped, 
blended with hydroxypropyl methyl cellulose or carbopol 934 in order to evaluate its potential 
for targeted sustained delivery of clarithromycin in the gastric region. 
Methods: Buoyant beads of gellan was developed by inotropic gelation technique using calcium 
carbonate as gas forming agent and the drug polymer dispersion was emulsified with mineral 
oil. The oil was entrapped and blended with hydroxypropyl methyl cellulose or carbopol 934. 
The developed beads were evaluated in terms of diameter, % floating, encapsulation efficiency, 
In vitro drug release, In vivo gastric residence efficacy and clarithromycine concentration in the 
mucosa of the experimental animal model. 
Results: The scanning electron microscope photograph indicated that the prepared beads were 
spherical in shape and buoyancy, encapsulation efficiency and drug content obtained from all 
batches were satisfactory. Particle size and percentage buoyancy of the gel beads increased by 
raising the concentration of calcium carbonate. The formulation exhibited sustained release 
profile and was best fitted in the Peppas model with n < 0.45. Subsequent coating of microbeads 
exhibited zero-order sustained pattern of the drug release up to 8 hrs. Batch B4 showed 
comparatively better residence and the drug concentration in the gastric mucosa of the treated 
animals. 
Conclusion: The result provides evidence that the prepared optimized formulation may be used 
effectively for pH sensitive gastric targeted antibiotic such as clarithromycin.
Keywords: pH sensitive drug delivery system, Hydrophilic polymer, Buoyancy, Gastric 
retention 
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INTRODUCTION
 Oral delivery systems that can precisely control the 
release rate of target drug in a specific site of gastro -
intestine (GI) have an enormous impact on the health 
care system. Gastroretentive drug delivery system is 
an approach to prolong gastric residence time and 
appropriate for drugs which should be locally active 
in the gastric mucosa in the stomach, in particular 
antibiotics administration for Helicobacter  pylori 
(H. pylori) eradication in the treatment of peptic 
ulcer and other diseases (1).
Helicobacter pylori (H. pylori) is a small, spiral, 
microaerophilic, gram-negative bacteria which 
has been recognized to be associated with gastritis 
and duodenal ulcers. The microorganism has also 
been reported to be involved in the pathogenesis 
of other diseases, such as chronic atrophic gastritis, 
adenocarcinoma of the body or antrum of the 
stomach, gastro-esophageal reflux diseases, peptic 
esophagi and etc (2, 3). The bacteria penetrates to 
the  gastric  mucous  layer  and  fix  itself  to  various 
phospholipids and glycolipids in the mucus gel. 
Therefore, access of antimicrobial drugs to the site 
is restricted from both the lumen of the stomach and 
the gastric blood supply. Gastroretentive systems 
have gained considerable attention due to their 
ability to adhere to the mucus layer, as well as to 
release the drug in a sustained manner in the mucosa 
of the stomach (4). The extended release of the drug 
can maintain a higher antibiotic concentration in the 
gastric region where H. pylori exists and thereby 
improve the therapeutic efficacy. The bioadhesive 
drug delivery system can plug and seal the infected 
and inflamed mucosal cell lines (5). Preparation and 
evaluation  of  stomach-specific  controlled  release 
mucoadhesive drug delivery system containing acid-
soluble drug amoxicillin trihydrate has been reported 
(6). Also, gellan gum based floating beads containing 
clarithromycin have been prepared by iontotropic 
gelation method for stomach-specific drug delivery 248 Formulation and In Vitro evaluation of beads of clarithromycin
against H.pylori and have shown good antibacterial 
activities against isolated H. pylori strains (7). 
Clarithromycin (Cl) is a broad spectrum macrolide 
antibacterial agent that is primarily bacteriostatic 
and  its  mechanism  of  action  is  binding  to  the                    
50 S ribosomal subunit of susceptible organism and 
inhibiting protein synthesis (8).  
The primary objective of the present work was 
to develop a consistent formulation of Cl that 
enjoys all the advantages of a floating single unit 
dosage form but at the same time being devoided 
of disadvantages of single unit dosage forms, like 
sticking or being obstructed in the gastrointestinal 
tract. 
MATERIAL AND METHODS
Materials
Clarithromycin was obtained as gift sample from 
Ranbaxy Laboratories Ltd, Gurgoan, India. Gellan 
gum was purchased from Sigma-Aldrich Chemicals 
Ltd, New Delhi, India. Carbopol 934P and 
Hydroxypropyl methylcellulose K4M were obtained 
as a gift samples from, Ranboxy laboratory Devash, 
India. Calcium chloride and ethyl cellulose were 
obtained from S.D. Fine Chem. India. Light mineral 
oil was obtained from the Central Drug House, India. 
All other ingredients, reagents and solvents were of 
analytical grades.
Methods
Preparation of polymeric blend oil entrapped bead
Oil entrapped polymeric blend gel bead of 
clarithromycin was prepared by ionic gelation 
method. Aqueous solution of gellan gum (1.5-2.0 
% w/v) was prepared using de-ionized water and 
heating at 70°C. The gellan gum solution below 
35°C was successively dispersed into the slurry of 
0.5 -1.0 % w/v of HPMC or carbopol 934P in order to 
prepare specific ratio of blended polymeric dispersion 
(Table 1) with continue stirriring for 20 min. The 
drug (0.54 % w/v) and calcium carbonate (0.55-1.5 
% w/w) were dispersed uniformly into 20 ml of the 
polymeric blended mixture with continuous stirring 
until a uniform dispersion was obtained. The mixture 
was emulsified with 05-15 % w/v of light mineral 
oil using Silverson emulsifier (Hicon, L5M-4, India) 
with continuous stirring at 500 rpm for 5 min. 
The resulting drug loaded emulsions was added 
through a 21G syringe needle into 100 ml of 0.45 
mol ml -1 of calcium chloride (CaCl2) solution. After 
5 min of curing time, the formed beads were washed 
with distilled water, collected and dried at 40°C for 
6 hrs.  
  
Coating of gel beads
Formulated microgel beads were selected for 
optimization in order to modify drug release pattern 
further. The coating parameters were 5-10% (w/v) 
ethylcellulose (EC) solution in acetone and coating 
times was fixed (5- 10 min). Gel beads (2 gr) were 
placed in a fluidized bed dryer (TG 100, Retsch, 
Germany) and the coating solution was sprayed on 
the fluidized beds using a spray gun for a period 
of 10 min at room temperature at an air inlet 
speed of 220 ms-1. The beads were dried at room 
temperature for a period of 24 hrs until all solvent 
was evaporated, leaving a film of EC coat on the gel 
beads (Table 2).  
Morphology and particle size 
The external and internal morphology of microgel 
beads were studied by scanning electron microscopy 
(SEM). Particle size of the prepared beads were 
determined using an optical microscope (Model 
BH-2, Olympus, Japan) fitted with a stage and an 
ocular micrometer. Mean diameter was calculated 
Formulation Drug Gum Oil Calcium carbonate
(COB) (HOB) (% w/v) ( % w/w) ( % w/v) (% w/v)
B1 N1 0.54 1.5:1.0 05 0.55
B2 N2 0.54 1.5:1.0 10 0.55
B3 N3 0.54 1.5:1.0 15 0.55
B4 N4 0.54 1.5:1.0 05 1.5
B5 N5 0.54 2.0:0.5 05 0.55
B6 N6 0.54 2.0:0.5 10 0.55
B7 N7 0.54 2.0:0.5 15 0.55
B8 N8 0.54 2.0:0.5 05 1.5
COB = gellan : carbopol blended formulation       
HOB= gellan: hydroxypropyl methylcellulose (HPMC) blended formulation
Gum = gellan: carbopol /HPMC
Oil = mineral oil
Table 1. Composition of the drug loaded polymeric blended gellan gum bead.249 Formulation and In Vitro evaluation of beads of clarithromycin
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by measurement of diameter of 20 dried beads. 
In vitro floating study  
In vitro floating study was performed using a 
USP-24 dissolution apparatus II containing 900 
ml of simulated gastric fluid (SGF) of pH 1.2. The 
medium temperature was kept at 37±0.5 °C. The 
floating  beads  (1.0  gr  beads)  were  soaked  in  the 
dissolution medium and the medium was agitated 
with a paddle at 50 rpm. After agitation, the beads 
that  floated  on  the  surface  of  the  medium  and 
those that settled down at bottom of the flask were 
recovered separately. The percentage of floating was 
measured by visual observation (9). 
Encapsulation efficiency and drug content 
Accurately weighed (100 mg) grounded powder of 
beads was soaked in 100 ml phosphate buffer (pH 7.5) 
and allowed to disintegrates completely for 4 hrs (9). 
The resulting dispersion was sonicated using a probe 
sonicator (UP 400 s, Dr. Hielscher GmbH, Germany) 
for 30 min and then filtered through a 0.45 μm filter. 
The polymeric debris was washed twice with fresh 
phosphate buffer to extract any adhered drug and 
drug content was determined spectrophotometrically 
at 353 nm against constructed calibration curve. 
The  drug  content  (DC)  was  calculated  according  to        
Eq 1. 
DC % = (amount of drug in beads /amount of beads) 
× 100.................................................................... (1)
The encapsulation efficiency (EE) was calculated by 
Eq 2. 
EE (%) = (C/T)× 100........................................... (2) 
Where C is the calculated drug content and T is the 
theoretical drug content.
Gastric residence efficacy of microbeads
Gastric  residence  efficacy  was  evaluated  by  the 
method of Zheng et al. (10) with slight modification. 
The protocol of the study was approved by the 
animal ethical committee of the department. Albino 
rats selected for the study were fasted for 8 hrs 
and then divided into two groups of three animals.   
Each groups was pre-treated by an intraperitoneal 
injection of omeprazole at the dose of 15 mg/Kg to 
suppress gastric acid secretion. After one hour of 
the administration of omeprazole, each group was 
given a single oral dose of 500 beads (batch B4 or 
batch N5 ) in aqueous suspension. After 1, 4, and 8 
hrs, the rats were scarified by cervical dislocation 
and the stomachs were removed. The microbeads 
that retained in the stomach were counted and the 
percentage of the remaining beads was calculated. 
Evaluation of concentration of the drug in gastric 
mucosa 
Albino rats were fasted for 8 hrs and then divided 
into three groups of three animals. The protocol 
of the study was approved by the animal ethical 
committee of the department. The animals were 
treated by an intraperitoneal injection of omeprazole 
at the dose of 15 mg/Kg to suppress gastric acid 
secretion. After one hour of omeprazole treatment, 
one group was treated with Cl plain and other groups 
were treated with formulation batches B4 and N5 at 
the equivalent dose of 40 mg/ Kg. The rats were 
sacrificed  at  1,  3,  6  hrs  after  administration,  the 
stomachs of the rates were removed and opened 
along the great curvature, residues in the stomachs 
were removed carefully, and the stomachs were 
gently rinsed in 20 ml of distilled water and spread 
on a glass slide, and the top layer was separated from 
the muscular layers (11). The removed mucosa was 
mixed with phosphate buffer pH of 7.4 in a glass 
tissue glinder and homogenate was centrifuged in a 
refrigerated ultracentrifuge at 3500 rpm for 5 min. 
The supernatant was removed and filtered through 
0.45 µm filter. The amount of Cl contained in sample 
was measured by spectrophotometric method at 353 
nm. 
In vitro drug release
In vitro dissolution studies were performed for all 
formulation gel beads using USP 24 dissolution 
test apparatus II with a basket type. An accurately 
weighed 50 mg amount of the beads were taken 
in to 900 ml dissolution medium of the simulated 
gastric fluid ( fasting state condition, pH of 1.2, ) or     
Formulation
(code )
EC concentration
(% w/v )
Time of coating
(min)
% drug release
t480 (min.)
a R2
B14 5 5 70±1.5 0.9424 
B24 5 10 80±1.6 0.9745
B34 10 5 72±1.7 0.9313
B44 10 10 69±1.2 0.9232
EC = ethyl cellulose
R2 = correlation coefficient derived from zero order drug release kinetics.
B14, B24, B34 and B44 = ethylcellulose coated optimized formulation of batch B4.
a = Mean ± SD (n = 3)
Table 2. Independent variables of the formulation bead coated with ethyl cellulose.250 Formulation and In Vitro evaluation of beads of clarithromycin
phthalate buffer solution, (fed state condition, pH of 
3.4) and maintained at a temperature of 37ºC ± 0.5°C 
and stirred at a speed of 50 rpm. Sample aliquots (10 
ml) were withdrawn at 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 
6.0, 7.0 and 8.0 hrs and volumes were replaced with 
an equivalent amount of the dissolution medium. 
The collected samples were filtered and analyzed 
at 353 nm using a UV-visible spectrophotometer. 
Additionally, an experimental batch F(fed state ) and 
batch FF(empty state ) containing 10 mg of Cl and 
lactose (q.s.) filled in a capsule (# 2) was used as a 
reference formulation. 
Statistical analyses
The experimental results are expressed as mean ± SD. 
Statistical evaluation of data was performed using an 
analysis of variance (ANOVA). The evaluation data 
was used to assess the significance of differences. 
Statistically  significant  difference  between  the 
means of batches were defined as P<0.05. 
RESULTS AND DISCUSSION 
   
Morphology and Particle size 
Spherical gel beads were formed instantaneously 
when emulsion was dropped into CaCl2 solutions. 
Gelation occurred due to intermolecular cross-
linking between the divalent calcium ions (Ca+2)   
and the negatively charged carboxyl groups of gellan 
gum. SEM of Cl loaded oil entrapped blended with 
carbopol 934P (formulation COB) beads were white, 
translucent and rigid and HPMC blended (formulation 
HOB) beads were found to be spherical with smooth 
surfaces. The diameter of COB formulation varied 
between 1.05±0.8 mm. to 1.48±0.3 mm. while 
that of HOB was 0.94±0.4 mm. to 1.30±0.5 mm. 
Size distribution pattern of micro beads of both 
formulations  showed  significance  differences  (Fig 
1). The diameter of the beads increased significantly 
(p<0.05) as polymer concentration increased; which 
could be attributed to the increase in the micro-
viscosity of the polymeric dispersion, eventually 
leading to the formation of bigger beads. Larger 
size beads were also formed as the concentration of 
calcium carbonate (CaCO3) increased. This may be 
due to excess Ca+2 causing all possible cross-linking 
sites in the polymer to be fully utilized, resulting in 
large but weaker and flexible gel beads. 
In vitro floating study 
The formulations batch B4 and batch N5 were 
found to have good floating ability (92±1.2 % and 
89±1.3 % respectively). The floating ability of the 
formulation mainly depends on CaCO3 and blended 
polymer ratio. Similar finding have been reported 
by Rajinikanth and Mishra (7) on evaluation of 
gellan bead of clarithromycin. By increasing CaCO3 
concentration, floating percentage of the micro gel 
beads increased. The increase in amount of Ca+2 
and consequently the amount of the evolved carbon 
dioxide gas (CO2), are entrapped in the gel network 
of the formulation, cause the gel rises to the surface 
of the dissolution medium (in vitro) or the stomach 
(12).  
Encapsulation efficiency and drug content 
Encapsulation of the drug was found to be 
consistently higher in the prepared formulations 
of COB (75±0.7-93± 0.4%) and HOB (70±0.5- 
86±0.6%).  No  significant  (P>0.05)  effect  was 
observed for CaCO3 concentration on encapsulation 
efficiency of the prepared gel bead. The drug content 
of COB formulation was found to be in the range 
of 58±1.4 to 78±1.6% w/w. HOB formulation was 
found to be in the range of 44±1.6 to 68±1.8 % w/w. 
No  significant  (P>0.05)  effect  was  observed  with 
CaCO3 and CaCl2 on drug content of beads.  
Gastric residence efficacy of microbeads
Gastric residence studies were carried out to ensure 
the transit of the designated formulation in the 
gastric  mucosa.  Profile  of  the  percentage  of  the 
gastric residence of the microbeads is shown in 
figure 2. Gastric retention of selected batch B4 and 
batch N5  were found 45±1.2 % and 37±1.5 % at 8 
hrs of the study. Significant difference of the gastric 
retention of batch B4, may be due to the affinity of 
the formulation to glycoproteins of the mucous layer 
of the stomach. The formulation was floated in the 
stomach and later adhered to the mucous layer so 
both mechanisms enhanced the gastric residence 
time.
Evaluation of the concentration of the drug in gastric 
mucosa 
The drug concentration in gastric mucosa of the 
experimental animal was evaluated in order to assess 
availability of the drug in the vicinity of mucosal 
layer in different time period. The pattern of release 
of Cl from the formulation of batch B4, batch N5 and 
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Figure 1: Mean particle size distribution pattern of different batches of formulations 
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efficiency of the prepared gel bead. The drug content 
of COB formulation was found to be in the range 
of 58±1.4 to 78±1.6% w/w. HOB formulation was 
found to be in the range of 44±1.6 to 68±1.8 % w/w. 
No  significant  (P>0.05)  effect  was  observed  with 
CaCO3 and CaCl2 on drug content of beads.  
Gastric residence efficacy of microbeads
Gastric residence studies were carried out to ensure 
the transit of the designated formulation in the 
gastric  mucosa.  Profile  of  the  percentage  of  the 
gastric residence of the microbeads is shown in 
figure 2. Gastric retention of selected batch B4 and 
batch N5  were found 45±1.2 % and 37±1.5 % at 8 
hrs of the study. Significant difference of the gastric 
retention of batch B4, may be due to the affinity of 
the formulation to glycoproteins of the mucous layer 
of the stomach. The formulation was floated in the 
stomach and later adhered to the mucous layer so 
both mechanisms enhanced the gastric residence 
time.
Evaluation of the concentration of the drug in gastric 
mucosa 
The drug concentration in gastric mucosa of the 
experimental animal was evaluated in order to assess 
availability of the drug in the vicinity of mucosal 
layer in different time period. The pattern of release 
of Cl from the formulation of batch B4, batch N5 and 
were found to be spherical with smooth surfaces. The diameter of COB formulation 
varied between 1.05±0.8 mm. to 1.48±0.3 mm. while that of HOB was 0.94±0.4 mm. to 
1.30±0.5 mm. Size distribution pattern of micro beads of both formulations showed 
significance differences (Fig 1). The diameter of the beads increased significantly (p < 
0.05) as polymer concentration increased; which could be attributed to the increase in 
the micro-viscosity of the polymeric dispersion, eventually leading to the formation of 
bigger beads. Larger size beads were also formed as the concentration of calcium 
carbonate (CaCO3) increased. This may be due to excess  Ca
+2 causing all possible 
cross-linking sites in the polymer to be fully utilized and resulting in large but weaker 
and flexible gel beads.  
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Figure 1: Mean particle size distribution pattern of different batches of formulations 
Hydroxypropyl Methylcellulose (HPMC) Blended Formulation (HOB) and 
Carbopol Blended Formulation (COB)  
 In vitro floating study
The formulations batch B4 and batch N5 were found to have good floating ability 
(92±1.2 % and 89±1.3 % respectively). The floating ability of the formulation mainly 
depends on CaCO3 and blended polymer ratio. Similar finding have been reported by 
Figure 1. Mean particle size distribution pattern of different 
batches of formulations Hydroxypropyl Methylcellulose (HPMC) 
Blended Formulation (HOB) and Carbopol Blended Formulation 
(COB).
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Formulation
Diameter
(mm)a,b Floating ability (%)a Encapsulation Efficiency
(%w/w)a, c Drug content % a, c
COB HOB COB HOB COB HOB COB HOB COB HOB
B1 N1 1.05±0.8 0.94±0.4 95±1.4 86±1.4 78±0.6 73 ±0.3 66± 1.5 54±1.4
B2 N2 1.10±0.5 1.02±0.5 92±1.6 83±1.6 82± 0.4 70 ±0.5 60±1.8 47±1.5
B3 N3 1.37±0.5 1.08±0.6 87±1.4 78±1.4 75±0.7 72 ±0.5 58±1.4 44±1.6
B4 N4 1.48±0.3 0.99±0.4 92±1.2 80±1.5 95±0.8 81 ± 0.4 78±1.6 63±1.4
B5 N5 1.28±0.8 1.30±0.5 84±1.3 89±1.6 93±0.4 86 ± 0.6 70±1.9 68±1.8
B6 N6 1.40±0.6 1.22±0.6 76±1.4 73±1.5 83±0.5 78 ± 0.4 61±1.7 66±1.5
B7 N7 1.08±0.2 1.07±0.6 71±1.4 70±1.4 84±0.4 81 ± 0.8 63±1.3 60±1.6
B8 N8 1.23±0.3 1.20±0.2 79±1.4 73±1.5 81±0.8 79 ± 0.5 62±1.6 58±1.3
COB = gellan-carbopol blended formulation.
HOB = gellen -HPMC blended formulation.
a = Mean ± SD (n = 3)
b = number of micro beads taken for determination of particle size (n = 20)
c = Drug content in each100 mg of bead
Table 3. Characteristics of prepared formulation of polymeric blended gellan gum gel beads.
plain claritromycine (batch Cl) are shown in figure 
3. The drug was released from the formulation and 
attained initially concentration of 40±0.05 µg/ml 
(batch B4), 34±0.02 µg/ml (batch N5) and 20±0.06 
µg/ml (batch Cl). Thus, high concentration of the 
drug release was from the batch B4 in to the gastric 
mucosa because of the partition of the drug from the 
formulation barrier.  
In Vitro drug release studies 
Study of the In vitro Cl release of gel beads was 
carried out both in the SGF solution (fasting state) 
and in phthalate buffer (fed state) for a period of 
8 hrs. The results indicate that 88±1.2 % of the 
pure drug (batch F) was dissolved within 2 hrs in 
fasting state (pH of 1.2) and in the fed state (batch 
FF, pH of 3.4), the release was 86.9±1.6 %..After 
8hrs, drug release from batch B4 was 62.0±2.2 % 
(fasting state) from the batch B4F was 57.0±2.5 % 
(fed state) in the SGF and phthalate buffer solution 
(Fig 4a) respectively. Drug release from the 
optimized formulations B4 followed the Higuchi     
(R2=0.924) and Peppas models (R2=0.936, n=0.36) 
and suggested a diffusion based mechanism of the 
drug release as the diffusion exponent values were 
less than 0.45(13-16). However, the dissolution 
profiles of all EC- coated beads were best fitted 
to the zero-order kinetic model (Fig 4B). The 
batch B24  which  showed  highest release (Table 
2) of clarithromycin (80±1.6%) was regarded as 
pH sensitive controlled release formulation of 
clarithromycin.
      
CONCLUSION
The developed optimized formulation is anticipated 
to maintain minimum inhibitory concentration 
(MIC) of clarithromycin at the infection site 
and allowing penetration of the drug inside the 
mucous gel initially. It is also anticipated that 
the developed formulation release the drug to the 
eradicate infection lesion in the acidic region of the 
gastrointestinal tract. Hence clarithromycin delivery 
system which was designed, not only could curtail 
and alleviate the shortcomings of conventional 
drug delivery vehicles, but also targeted to deliver 
antimicrobial agents like clarithromycin to the 
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Figure 2:   Gastric residence pattern of batch B4 and N5 in the stomach in different 
time interval. 
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Figure 3:  Drug concentration in gastric mucosa of the experimental animal treated with 
batch B4 , N5 and Cl in different time intervals. 
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Figure 4:  Comparative drug release profile: (4a) fasting and fed state condition (4b)  
 ethyl cellulose coated batch B4 . 
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